Reason for request
Inclusion
-
Clinical Benefit
Substantial |
The actual benefit of ADCETRIS is substantial in the indications of the Marketing Authorisation. |
Clinical Added Value
moderate |
Despite very limited data, but given the high response rate and the absence of a validated therapeutic alternative, the Transparency Committee is of the opinion that ADCETRIS offers a moderate improvement in actual benefit (IAB III) in terms of efficacy in the treatment of adults - with relapsed or refractory CD30+ Hodgkin lymphoma following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option. - with relapsed or refractory systemic anaplastic large cell lymphoma. |
English version
Contact Us
Évaluation des médicaments